Relation between hormone replacement therapy and ischaemic heart disease in women: Prospective observational study

British Medical Journal

Volumn 326, Issue 7386, 2003, Pages 426-428

  Lokkegaard E ^a   Pedersen, A T ^a   Heitmann, B L ^e   Jovanovic, Z ^c   Keiding, N ^c   Hundrup, Y A ^d   Obel, E B ^d   Ottesen, B ^b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e The Capital Region   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DEATH; DENMARK; DIABETES MELLITUS; FEMALE; HAZARD ASSESSMENT; HEART INFARCTION; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; NORMAL HUMAN; NURSE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; SELF EVALUATION; SMOKING;

AGED; DENMARK; DIABETES MELLITUS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0037460695     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hu FB, Stampfer MJ, Manson JE, Grodstein F, Colditz GA, Speizer FE, et al. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Eng J Med 2000;343:530-7.
2. Grady D. Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women [see comments], Ann Intern Med 1992;117:1016-37.
3. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995:38:199-210.
4. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? [see comments]. Am J Epidemiol 1996;143:971-8.
5. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002;288:872-81.
6. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
7. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-9.
8. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group [see comments]. JAMA 1998;280:605-13.
9. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
10. Hundrup YA, Obel EB, Rasmussen NK, Philip J. Use of hormone replacement therapy among Danish nurses in 1993. Acta Obstet Gynecol Scand 2000;79:194-201.
11. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo study. JAMA 1991;265:627-31.
12. Cornu C, Mercier C, French P, Bully C, Pugeat M, Cousin P, et al. Postmenopause hormone treatment in women with NIDDM or impaired glucose tolerance: the MEDIA randomized clinical trial. Maturitas 2000;37:95-104.
13. Triusu RJ, Cowie CC, Harris MI. Hormone replacement therapy and glucose metabolism. Obstet Gynecol 2000;96:665-70.
14. Andersson B, Mattsson LA, Hahn L, Marin P, Lapidus L, Holm G, et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997;82:638-43.
15. Friday KE, Dong C, Fontenot RU. Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2001;86:48-52.
16. Manwaring P, Morfis L, Diamond T, Howes LG. The effects of hormone replacement therapy on plasma lipids in type II diabetes. Maturitas 2000;34:239-47.
17. Koh KK, Rang MH, Jin DR, Lee SK, Ahn JY, Hwang HY, et al. Vascular effects of estrogen in type II diabetic postmenopausal women. J Am Coll Cardiol 2001;38:1409-15.
18. Brussaard HE, Gevers Leuven JA, Frolich M, Kluft C, Krans HM. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia 1997;40:843-9.
19. Rodstrom K, Bengtsson C, Lissner L, Bjorkelund C. Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort study in Gothenburg, Sweden. BMJ 1999;319: 890-3.
20. Hundrup YA, Thoning H, Obel EB, Rasmussen NK, Philip J. Lifestyle factors and choice of hormone replacement therapy among Danish nurses. Scan J Public Health 2002;30:47-53.